BFRI

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: AKAN APUS AYTU CPHI RMTI TXMD BGM CTOR SCYX SCLX

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	14.08M
Enterprise Value	15.47M
Income	-11.09M
Sales	43.20M
Book/sh	0.51
Cash/sh	0.49
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	92
IPO	Oct 29, 2021

P/E	-
Forward P/E	5.79
PEG	-
P/S	0.33
P/B	2.15
P/C	2.22
P/FCF	-
EV/EBITDA	-
EV/Sales	0.36
Quick Ratio	1.09
Current Ratio	1.20
Debt/Eq	1.27
LT Debt/Eq	1.19
Option/Short	No / Yes

EPS (ttm)	-1.11
EPS next Y	0.19
EPS next Q	-0.10
EPS this Y	77.88%
EPS next Y	182.61%
EPS next 5Y	-
EPS past 3/5Y	-19.60% 44.08%
Sales past 3/5Y	13.30% 17.21%
EPS Y/Y TTM	33.33%
Sales Y/Y TTM	13.70%
EPS Q/Q	14.13%
Sales Q/Q	17.42%
Earnings	May 14 BMO
EPS/Sales Surpr.	-256.52% -1.62%

Insider Own	14.96%
Insider Trans	0.00%
Inst Own	19.89%
Inst Trans	1.99%
ROA	-53.58%
ROE	-339.04%
ROIC	-83.42%
Gross Margin	84.91%
Oper. Margin	-16.96%
Profit Margin	-25.66%
SMA20	7.87%
SMA50	11.84%
SMA200	18.81%
Trades

Shs Outstand	11.87M
Shs Float	10.89M
Short Float	0.26%
Short Ratio	0.11
Short Interest	0.03M
52W High	1.21 -8.71%
52W Low	0.55 98.31%
Volatility	10.40% 9.08%
ATR (14)	0.09
RSI (14)	57.44
Beta	0.82
Rel Volume	1.38
Avg Volume	254.18K
Volume	351,826

Perf Week	8.91%
Perf Month	25.00%
Perf Quarter	5.77%
Perf Half Y	37.84%
Perf YTD	92.98%
Perf Year	29.72%
Perf 3Y	-88.17%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	6.00
Prev Close	1.14
Price	1.10
Change	-3.51%

Date	Action	Analyst	Rating Change	Price Target Change
May-19-26	Downgrade	The Benchmark Company	Buy → Speculative Buy	$3

May-19-26 09:34AM	StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls (The Fly)
May-14-26 07:04PM	Biofrontera Inc (BFRI) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com) -19.08%
Mar-20-26 09:01PM	Biofrontera Inc (BFRI) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Mar-19-26 12:44PM	Biofrontera Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-09-26 12:00PM	Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why (Zacks)
09:55AM	Loading…
Feb-05-26 09:55AM	Biofrontera Inc. (BFRI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks) -5.59%
09:40AM	Is Biofrontera Inc. (BFRI) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-13-25 04:06PM	Biofrontera Inc (BFRI) Q3 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... (GuruFocus.com) -8.59% -8.13%
Nov-10-25 08:25AM	Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Nov-06-25 05:40PM	Lifecore Biomedical (LFCR) Reports Q1 Loss, Beats Revenue Estimates (Zacks) +6.42% -6.90%
Nov-05-25 08:20AM	Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.83%
Nov-04-25 05:25PM	PTC Therapeutics (PTCT) Q3 Earnings and Revenues Top Estimates (Zacks) -6.36%
Oct-24-25 08:55AM	Biofrontera Inc. close purchase of all Ameluz, RhodoLED U.S. assets (TipRanks)
Aug-25-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-15-25 03:20AM	Biofrontera Inc (BFRI) Q2 2025 Earnings Call Highlights: Record Revenue Growth Amid Operational ... (GuruFocus.com)
05:20PM	Loading…
Aug-13-25 05:20PM	Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-12-25 05:10PM	Lineage Cell (LCTX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-11-25 04:25PM	Biofrontera Inc. Appoints George Jones as Chief Commercial Officer (GlobeNewswire)
Aug-07-25 07:00PM	Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -6.86%
Aug-06-25 06:00PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-04-25 02:00PM	Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025 (GlobeNewswire)
Jun-30-25 08:00AM	Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment (GlobeNewswire) +18.27%
Jun-11-25 03:00PM	BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG (GlobeNewswire) +6.05%
Jun-03-25 02:30PM	Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book (GlobeNewswire) +16.26%
May-15-25 05:09PM	Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire) -7.18%
12:17PM	Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris (GlobeNewswire)
May-13-25 05:15PM	Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag Estimates (Zacks) +5.32%
May-09-25 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-25 08:45AM	Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-06-25 12:45PM	Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025 (ACCESSWIRE)
02:38PM	Loading…
May-01-25 02:38PM	Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis (GlobeNewswire)
Mar-21-25 11:20AM	Biofrontera Inc. (BFRI) Q4 2024 Earnings Call Transcript (SeekingAlpha) -16.50%
08:00AM	Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Mar-18-25 09:30AM	Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk (GlobeNewswire)
Mar-11-25 10:00AM	Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025 (GlobeNewswire)
Jan-08-25 09:50AM	Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz -Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) (GlobeNewswire) +6.31%
Dec-23-24 09:30AM	Biofrontera Inc. Announces 100 RhodoLED XL Machines Now Placed in US Market (GlobeNewswire)
Dec-03-24 11:00AM	Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference (ACCESS Newswire) -6.39%
Nov-22-24 09:10AM	Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note (GlobeNewswire) +14.62%
Nov-13-24 05:15PM	Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update (GlobeNewswire) -11.54% -15.38%
Nov-01-24 11:55AM	Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 (ACCESSWIRE) -11.38%
Oct-31-24 10:32AM	Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz -Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) (GlobeNewswire) +31.71%
Oct-14-24 10:30AM	Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz -Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) (GlobeNewswire)
Oct-07-24 08:45AM	FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment (GlobeNewswire) -9.48%
Sep-25-24 10:45AM	Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference (ACCESSWIRE)
Aug-14-24 04:30PM	Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) -7.32%
Aug-09-24 10:00AM	Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024 (ACCESSWIRE)
Jun-24-24 08:30AM	Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED XL Lamp (GlobeNewswire) -5.35%
May-15-24 09:53PM	BFRI Stock Earnings: Biofrontera Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -6.20% -9.92%
04:45PM	Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update (ACCESSWIRE)
May-06-24 10:30AM	Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024 (ACCESSWIRE)
May-03-24 08:50AM	Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants (ACCESSWIRE)
Mar-26-24 04:30PM	Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals (ACCESSWIRE) -5.45%
Mar-19-24 09:22AM	Biofrontera Inc. (NASDAQ:BFRI) Q4 2023 Earnings Call Transcript (Insider Monkey) -6.35%
Mar-15-24 09:52PM	BFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace) -11.43% -18.71%
08:25PM	CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update (ACCESSWIRE)
06:10PM	Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update (ACCESSWIRE)
Mar-08-24 09:00AM	Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024 (ACCESSWIRE)
Feb-23-24 08:40AM	Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules (ACCESSWIRE) -7.54%
Feb-20-24 08:10AM	Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG (ACCESSWIRE) +53.44%
08:05AM	Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules (ACCESSWIRE)
Feb-05-24 05:15PM	Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use (ACCESSWIRE)
Feb-02-24 08:07AM	Why Is Biofrontera (BFRI) Stock Down Today? (InvestorPlace) -31.09%
Jan-11-24 04:15PM	Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023 (ACCESSWIRE)
Nov-22-23 09:55AM	Biofrontera Inc. (BFRI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Nov-11-23 12:05PM	Biofrontera Inc. (NASDAQ:BFRI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 05:10PM	Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update (ACCESSWIRE) -5.78%
12:00PM	Biofrontera Inc. (BFRI) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-03-23 08:30AM	Biofrontera Inc. to Report Third Quarter 2023 Financial Results on November 9 and Hold Conference Call on November 10 (ACCESSWIRE) -9.11%
Oct-31-23 08:01AM	Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules (ACCESSWIRE) +23.68%
Oct-10-23 09:00AM	Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R) (ACCESSWIRE) -8.57%
Oct-05-23 09:00AM	Biofrontera Inc. to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference (ACCESSWIRE)
Oct-04-23 08:30AM	Biofrontera Inc. Announces Preliminary Third Quarter Revenues (ACCESSWIRE)
Aug-29-23 08:00AM	Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts (ACCESSWIRE)
Aug-28-23 08:00AM	Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R) (ACCESSWIRE)
Aug-11-23 08:25AM	Biofrontera Inc. (BFRI) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update (ACCESSWIRE)
Aug-10-23 08:30AM	Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma (ACCESSWIRE)
Aug-04-23 08:30AM	Biofrontera Inc. to Report Second Quarter Financial Results on August 11, 2023 (ACCESSWIRE)
Jul-13-23 09:00AM	Biofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31% (ACCESSWIRE)
Jul-12-23 08:00AM	Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors (ACCESSWIRE)
Jul-03-23 11:42AM	Breakeven On The Horizon For Biofrontera Inc. (NASDAQ:BFRI) (Simply Wall St.)
09:15AM	Biofrontera Inc. Announces 1-for-20 Reverse Stock Split (ACCESSWIRE)
Jun-12-23 09:00AM	Biofrontera Inc. Sponsors The Sun Bus, Delivering Free Mobile Skin Cancer Screenings Across the U.S. (ACCESSWIRE)
Jun-01-23 09:15AM	Biofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz(R)-PDT (ACCESSWIRE)
May-30-23 09:00AM	Biofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive Officer (ACCESSWIRE)
May-15-23 09:50AM	Biofrontera Inc. Announces U.S. Patent Issued for Photodynamic Therapy Protocol with Reduced Side Effects (ACCESSWIRE)
May-12-23 09:55AM	Biofrontera Inc. (BFRI) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -28.63%
08:12AM	BFRI Stock Earnings: Biofrontera Misses EPS, Revenue Estimates (InvestorPlace)
07:30AM	Biofrontera Inc. Reports First Quarter 2023 Financial Results and Provides a Business Update (ACCESSWIRE)
07:00AM	Biofrontera Inc. Announces Resignation of CEO (ACCESSWIRE)
May-11-23 09:00AM	Biofrontera Inc. Announces New Secured Line of Credit up to $6.5 Million (ACCESSWIRE) -5.22%
May-09-23 09:00AM	Biofrontera Collaborates with The Skin Cancer Foundation to Raise Awareness of Skin Cancer Prevention (ACCESSWIRE)
Apr-28-23 10:00AM	Biofrontera Inc. to Report First Quarter 2023 Financial Results on May 12, 2023 (ACCESSWIRE)
Apr-26-23 10:00AM	Biofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz(R) (ACCESSWIRE) -5.34%
Mar-27-23 08:00AM	Biofrontera Inc. Makes Transformative Investment in Its' Dermatology Salesforce (ACCESSWIRE)
Mar-17-23 01:30PM	Biofrontera Inc. to Attend 2023 American Academy of Dermatology Annual Meeting (ACCESSWIRE)
Mar-11-23 07:50AM	Biofrontera Inc. (NASDAQ:BFRI) Analysts Just Slashed Next Year's Estimates (Simply Wall St.)
Mar-10-23 02:25AM	Biofrontera Inc. (NASDAQ:BFRI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 08:20AM	CORRECTING AND REPLACING: Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results (ACCESSWIRE) -10.24%

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company focuses on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.

CEODr. Hermann Luebbert Ph.D.

Chief Financial OfficerMr. Eugene Frederick Leffler III

Chief Commercial OfficerMr. George P. Jones

M.B.A.Ms. Erica F. Gates CPA

Ph.D.Mr. Jon Lyons M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Biofrontera Inc

Upgrade your Finviz experience